Team

Healthcare

Serge Belanger

Serge Belanger
Senior Analyst, Specialty Pharmaceuticals & Biopharmaceuticals

Telephone: (212) 705-0407
Email: sbelanger@needhamco.com

Serge Belanger joined Needham & Company in 2009. Prior to Needham, Serge worked as a research associate at Fulcrum Global Partners and Susquehanna International Group covering the biotech and specialty pharma healthcare sectors. Previously, Serge joined Adolor Corporation, a biopharmaceutical company, as a senior research scientist, where he was involved with the discovery and development of novel opioid receptor targeted molecules and non-opioid pain therapeutics. Serge graduated from McGill University with a BSc, Biochemistry/Pharmacology, and an MSc, Pharmacology and Therapeutics. He obtained his MBA in Finance from the Stern School of Business at New York University.

Danielle Brill, Pharm.D., BCPS
Senior Analyst, Biotechnology and Biopharmaceuticals

Telephone: (212) 705-0405
Email: dbrill@needhamco.com

Danielle Brill joined Needham & Company, LLC in 2015. Before joining Needham, she worked as a clinical pharmacist at Mount Sinai Hospital in New York City. Prior to her clinical pharmacy experience, Danielle worked in research laboratories focused on the development of novel therapeutics for lymphoid malignancies at Columbia Presbyterian and NYU Langone. She received her Bachelor’s degree in Biology from Michigan State University and earned her Pharm.D. from Ernest Mario School of Pharmacy at Rutgers, where she graduated summa cum laude. She also completed an internal medicine pharmacy residency at Mount Sinai Hospital and is a board certified pharmacotherapy specialist..

Kevin Caliendo

Kevin Caliendo
Senior Analyst, Healthcare Services

Telephone: (212) 705-0466
Email: kcaliendo@needhamco.com

Kevin Caliendo joined Needham & Company, LLC in 2016. He has over 20 years of Wall Street experience, primarily analyzing and investing in the healthcare industry. From 2014 until joining Needham, he worked at Deimos Asset Management as a portfolio manager. Previously, Kevin was a healthcare portfolio manager at SAC Capital, FrontPoint Partners, and Clearbridge Advisors. He earned his Bachelors of Science degree in Journalism from Boston University in 1993, and sits on the Dean of the College of Communication’s Advisory Board.

Alan Carr, Ph.D., CFA
Senior Analyst, Biotechnology

Telephone: (212) 705-0435
Email: acarr@needhamco.com

Alan Carr joined Needham & Company in 2006. From 2001 to 2006 Alan worked in Yale’s technology transfer group, the Office of Cooperative Research, where he out-licensed a number of technologies and therapeutic product candidates developed in Yale labs and helped establish start-up companies in the New Haven area. Prior to that he was at J. Bush & Co., a New Haven investment firm, where he covered companies in the research tool and healthcare space. His post-doctoral work was centered on the regulation of neuronal development during embryogenesis. He earned his undergraduate degree at Albion College and earned his Ph.D. in Molecular Biophysics and Biochemistry from Yale University.

Mike Matson

Mike Matson, CFA
Senior Analyst, Medical Technologies & Diagnostics

Telephone: (212) 705-0346
Email: mmatson@needhamco.com

Mike Matson joined Needham & Company in 2013 covering Medical Technologies & Diagnostics. Prior to joining Needham, Mike spent nine years covering the medical supplies and devices industry for Mizuho Securities and Wells Fargo Securities. He previously worked in the medical device industry for Stryker's Orthopaedics and Endoscopy divisions in marketing and product development. Mike has received multiple awards for stock picking and earnings estimate accuracy. Most recently, he was ranked first for stock picking in the Health Care Equipment & Supplies sector in the 2017 Thomson Reuters Analyst Awards. He was also ranked tenth in the TipRanks Top Ten Analysts of 2016 (across all sectors), third for earnings estimate accuracy in the Health Care Equipment & Supplies sector in the 2014 Thomson Reuters Analyst Awards, first for earnings estimate accuracy in the Health Care Equipment & Supplies sector in the 2013 Thomson Reuters Analyst Awards, second for stock picking in the Health Care Equipment & Supplies sector in the 2008 Thomson Reuters Analyst Awards, and fourth in the medical device sector for stock picking in the 2007 Wall Street Journal Best on the Street. Mike has a BS in Mechanical Engineering from North Carolina State University with a minor in Economics and a MBA from Duke University's Fuqua School of Business with a concentration in Health Sector Management. Mike holds a medical device patent (U.S. patent 6,919,914).

Chad Messer

Chad Messer, Ph.D.
Senior Analyst, Biotechnology

Telephone: (212) 705-0317
Email: cmesser@needhamco.com

Chad Messer joined Needham & Company in 2012. Prior to Needham, he was a research analyst at Piper Jaffray and Paramount Biocapital covering the biotechnology industry. In addition, Chad worked at Genaissance Pharmaceuticals, a New Haven, CT biotechnology company, where he held a number of positions, including manager of corporate development. He has over a dozen years of corporate and Wall Street experience with the biotech industry. Chad holds a Ph.D. in Pharmacology from Yale, received a MBA from NYU Masters of Business degree in Finance and a Bachelor’s degree in Biology from Yale.

Ethan Potasnick
Research Associate, Medical Technologies & Diagnostics

Telephone: (212) 705-0488
Email: epotasnick@needhamco.com

Leadership | Clean Technologies | Communications | Enterprise Infrastructure | Healthcare | Industrial & Diversified Growth | Internet, Entertainment & Consumer | Semiconductors & Equipment | Software & Services
Equity Research